ClinicalTrials.Veeva

Menu
U

University of North Carolina at Chapel Hill | Institute of Global Health and Infectious Disease

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
MK-3475
Doxorubicin
Durvalumab
R-CHP
LY2835219
DNL126
Sotatercept
Fulvestrant
Atezolizumab

Parent organization

This site is a part of University of North Carolina at Chapel Hill

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 60 total trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lympho...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal demen...

Active, not recruiting
Frontotemporal Dementia
Drug: Open label - AL001
Drug: AL001

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Vincristine Placebo
Drug: Polatuzumab vedotin Placebo

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination wi...

Enrolling
Carcinoma, Hepatocellular
Drug: Tiragolumab
Other: Placebo

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Cr...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Everolimus
Drug: Belzutifan

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo
Locations recently updated

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer o...

Enrolling
Urinary Bladder Neoplasms
Neoplasm Metastasis
Drug: LOXO-435
Drug: Pembrolizumab

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, t...

Active, not recruiting
Breast Neoplasms
Drug: Fulvestrant
Drug: Pertuzumab

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors.The study aims ar...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Pembrolizumab
Drug: TAK-981

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

This is a Phase 3 trial of cadisegliatin in participants with Type 1 Diabetes Mellitus.

Enrolling
Diabetes Mellitus, Type 1
Drug: Placebo
Drug: Cadisegliatin 800 mg BID

The goal of this clinical trial is to evaluate the effects of using the SinuSonic on psychological and physical well-being in adults who have nasal/s...

Enrolling
Nasal Congestion and Inflammations
Sinus Congestion Chronic
Other: SinuSonic

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling
Diabetic Retinopathy
Other: Placebo
Drug: Fenofibrate

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants...

Active, not recruiting
Melanoma
Renal Cell Carcinoma (RCC)
Drug: INCB 99280 with Ipilimumab

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling
Solid Tumors
Hematologic Malignancies
Drug: Pembrolizumab
Drug: Lenvatinib

This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodefic...

Active, not recruiting
HIV Infection
Drug: ART
Drug: DOR/ISL

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...

Enrolling
Endometrial Cancer
Drug: INCAGN02385
Drug: pemigatinib

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxoliti...

Enrolling
ET (Essential Thrombocythemia)
Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
Drug: INCB057643
Drug: Ruxolitinib

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Enrolling
Eosinophilic Esophagitis
Drug: CC-93538

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic...

Active, not recruiting
Metastatic Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Drug: Cemiplimab
Biological: RP1

Trial sponsors

University of North Carolina (UNC) logo
Incyte logo
Lilly logo
Merck Sharp & Dohme (MSD) logo
Roche logo
Jaeb Center for Health Research logo
UNC Lineberger Comprehensive Cancer Center logo
N
Abbott logo
Acceleron Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems